Infectious and Inflammatory Skin Conditions

Key Points

• Skin conditions are often grouped as bacterial, viral, fungal, parasitic, or inflammatory reactions.
• Nursing priorities are early pattern recognition, complication risk screening, and timely escalation.
• Moisture, hygiene barriers, skin breaks, and immunologic vulnerability increase infection risk.
• Trigger identification and recurrence prevention are central for chronic inflammatory skin reactions.

Pathophysiology

Skin infection occurs when microbial organisms enter through compromised barrier sites or overgrow in moist, occluded, or traumatized areas. Organism type and host factors determine severity, spread potential, and treatment urgency. Bacterial processes may remain localized to skin and soft tissue or progress to multisystem involvement when untreated or when host defenses are limited.

Inflammatory skin conditions can be acute or chronic and are commonly linked to hypersensitivity, autoimmune activity, or environmental and stress triggers. Recurrence is common when triggers are not identified and controlled.

Atopic-dermatitis pathways involve barrier dysfunction with increased allergen/pathogen penetration, increased transepidermal water loss, and T-cell/cytokine-driven inflammation. Common findings include severe pruritus with excoriation risk and chronic lichenification in repeatedly scratched flexural regions. Atopic-disease progression can follow an atopic-march pattern that begins early in life, with eczema and food-allergy burden often peaking earlier while allergic-rhinitis and asthma burden persists later. Filaggrin loss-of-function pathways and skin-pH dysregulation can weaken barrier integrity, increase dehydration risk, and amplify inflammatory signaling. Immune-pattern shifts (including Th2-dominant signaling relative to Th1 pathways) further reinforce IgE-linked hypersensitivity responses.

Contact-dermatitis pathways are commonly delayed hypersensitivity reactions that begin with sensitization in the epidermis (including antigen capture/processing and T-cell priming) and progress to a localized elicitation phase on re-exposure. This cytokine-driven response produces recurrent site-specific inflammation that can become chronic with ongoing exposure. Drug-reaction dermatitis (dermatitis medicamentosa) can occur through IgE-dependent or T-cell-mediated pathways after topical, oral, or parenteral drug exposure. Nonimmunologic mechanisms can also contribute (for example cumulative drug effect, photosensitization, irritant sensitivity, or host predisposition), so onset may vary from rapid to delayed.

Psoriasis pathways are immune-mediated and involve T-cell-driven keratinocyte hyperproliferation, thick plaque formation, epidermal hyperplasia, and parakeratosis. Beyond skin plaques, some patients report joint discomfort, nail changes, and sleep disruption during active inflammatory disease.

Classification

• Bacterial patterns: ecthyma (superficial-to-deeper crusting lesions), folliculitis (hair-follicle pustular pattern often linked to occlusion/moisture), carbuncle (clustered deep abscess pattern with scar risk), cellulitis (often unilateral warm erythematous edema) with systemic progression risk, and toxin-mediated staphylococcal exfoliative syndromes.
• Viral patterns: Herpes simplex (HSV-1 oral-contact pathways and HSV-2 sexual-contact pathways), varicella primary infection patterns, varicella-zoster reactivation (typically unilateral dermatomal shingles), COVID-19-associated cutaneous eruptions, and HPV-related verruca with vesicular/clustered or wart-like presentations.
• Pediatric viral-exanthem patterns: fifth disease (slapped-cheek evolution), hand-foot-and-mouth-disease (oral/hand/foot vesicular-ulcerative pattern), and molluscum-contagiosum (dome-like contact-spread lesions).
• Fungal patterns: Tinea variants (pedis, cruris, corporis, capitis, barbae, unguium/onychomycosis) and candidal involvement, often in warm/moist intertriginous regions and more frequent in obesity/diabetes contexts.
• Tinea-feature cluster: Pedis with toe-web scale/fissures, cruris with scaly groin-border rash, corporis with annular scaly border/central clearing, capitis with scaling plus patchy alopecia or kerion, and unguium with thickened brittle discolored nails.
• Parasitic patterns: scabies and pediculosis (capitis/corporis/pubic forms) with contact-spread and household/environmental decontamination needs.
• Inflammatory patterns: Eczema, seborrheic and diaper-dermatitis patterns, urticaria, acne, psoriasis, and lupus-related skin reactions driven by hypersensitivity, autoimmune, endocrine, or irritant-trigger pathways.
• Inflammatory-subtype cues: Eczema (atopy-linked acute oozing or chronic lichenified itch; often flexural in atopic disease), contact dermatitis (common irritant/allergen-trigger pattern including latex, poison-plant, and metal exposures), seborrheic dermatitis (greasy yellow scalp/face scale), urticaria (histamine-mediated wheals with angioedema risk), acne vulgaris (comedonal/papulopustular follicular inflammation), and rosacea (central-facial erythema/telangiectasia with papules and no comedones).
• Drug-reaction dermatitis cues: Medication-triggered eruptions can appear minutes to days after exposure, may include urticaria/pruritus/burning with or without rash, and can progress to systemic symptoms (for example fever, dyspnea, anaphylaxis).
• Contact-dermatitis subtype cues: Allergic, irritant, phototoxic, and photoallergic forms may be acute or chronic, with symptom onset that can appear hours to weeks after exposure.
• Contact-dermatitis phase cues: Acute phase often shows erythema with vesicles/blistering; subacute phase trends toward crusting over prior lesions; chronic phase can progress to thickened leathery lichenification.
• Severe inflammatory desquamation pattern: Generalized exfoliative dermatitis (erythroderma) can involve diffuse erythema/scaling over most of body surface area and requires hospital-level stabilization.
• Acne and psoriasis severity cues: Acne ranges from mild comedonal/papulopustular lesions to deeper nodulocystic scarring disease; psoriasis presents as recurrent, sharply bordered erythematous plaques with silvery scale and trigger-linked flares.
• Psoriasis subtype cues: Pustular disease can present with sterile pus-filled blisters (often palms/soles), while erythrodermic disease can present with diffuse peeling, burning-pruritic rash requiring urgent evaluation.

Nursing Assessment

NCLEX Focus

Differentiate likely condition category first, then prioritize contagiousness, tissue-compromise risk, and systemic warning signs.

• Assess lesion morphology, distribution, progression, pain/pruritus, and associated mucosal involvement.
• Screen for red flags: rapid spread, fever, severe pain, tissue necrosis, airway/facial involvement, or immunocompromised status.
• Evaluate skin-integrity contributors such as moisture exposure, hygiene barriers, scratching, and chronic disease burden.
• Identify recurrence triggers including stress, irritants, occlusion, and environmental or contact exposures.
• For bacterial-pattern assessment, check entry portals (scratches, bites, surgical incisions, fungal fissures, shaving friction) and document unilateral versus bilateral distribution.
• In impetigo/ecthyma patterns, distinguish bullous versus nonbullous lesions and identify honey or brown crust burden, punched-out ulcer depth, and self-contamination risk from scratching.
• In folliculitis/carbuncle patterns, assess maceration, occlusive-product use, contaminated-water exposure, and whether abscesses are interconnected with fever/chills or malaise.
• In folliculitis concern, include risk screening for diabetes, obesity, immunocompromise, prolonged antibiotic exposure, and contaminated pool/hot-tub history.
• In folliculitis patterns, document pruritus level, mild erythema pattern, and perifollicular papule/pustule clustering to separate localized superficial disease from deeper soft-tissue spread.
• In cellulitis patterns, assess for unilateral leg-predominant warmth, tenderness, edema, and possible vesicle/bulla formation; bilateral symmetric findings should trigger reassessment for alternate diagnoses.
• In recurrent staphylococcal or streptococcal patterns, anticipate need for carrier/decolonization strategy per local protocol.
• For viral-pattern assessment, document prodromal cues (burning/tingling pain), dermatomal distribution, and lesion stage (vesicle, crusting, healing).
• In herpes-simplex patterns, distinguish oral/labial versus genital/perianal/sacral lesion distribution, assess contact-spread exposure, and include perinatal-transmission risk screening when pregnancy is relevant.
• In herpes-simplex patterns, assess pre-eruptive tingling/itching and grouped vesicles on an erythematous base; escalate periocular lesions because keratitis risk can threaten vision.
• In varicella patterns, assess diffuse vesicular-stage progression, oral-lesion involvement, pruritus/scratching burden, and high-risk complications in immunocompromised or pregnancy contexts.
• In fifth-disease patterns, assess slapped-cheek rash progression, pregnancy or hemoglobinopathy risk context, and anemia-complication cues.
• In hand-foot-and-mouth-disease patterns, assess oral-ulcer pain with hydration status because poor intake can drive dehydration in pediatric clients.
• In molluscum-contagiosum patterns, assess clustered dome-like lesions with contact-spread exposure and secondary infection risk from scratching.
• In suspected staphylococcal-scalded-skin-syndrome, assess painful diffuse erythema, blistering/exfoliation, fluid-loss risk, and shock/sepsis indicators.
• In shingles patterns, verify unilateral dermatomal distribution that typically does not cross midline and escalate possible disseminated zoster when three or more dermatomes are involved in immunocompromised patients.
• In shingles patterns, assess viral prodrome (malaise/fever/local burning pain) and escalate facial or auricular dermatomal involvement promptly because vision/hearing complications can occur.
• In COVID-19 cutaneous patterns, document rash subtype (for example maculopapular, urticarial, petechial, vesicular, or chilblain-like toe lesions) and correlate with concurrent systemic illness trajectory.
• In verruca patterns, assess lesion subtype (for example plantar, palmar, periungual, filiform, flat, genital), pain with weight-bearing plantar lesions, and skin-break contact exposure history.
• For fungal-pattern assessment, inspect high-moisture skin folds and toe-web spaces and screen for diabetes/obesity contributors when recurrence is frequent.
• For suspected tinea-infection, classify by body site (capitis, corporis, cruris, pedis, versicolor) to guide focused treatment and teaching.
• In suspected tinea pedis, assess toe-web scaling/fissuring and secondary bacterial-infection cues from skin cracking.
• In tinea pedis/cruris patterns, assess footwear and clothing moisture burden (tight shoes, wet clothing, communal barefoot exposure) and recurrent maceration risk.
• In scalp or nail fungal disease, assess for hair-loss/scalp inflammation patterns, brittle-thickened nail changes, pain, and gait/balance impact.
• In tinea capitis concern, assess for black-dot or gray-patch hair-break pattern and for kerion (inflamed swollen painful pus-producing plaque) requiring escalation.
• For suspected scabies, assess for severe nocturnal pruritus, burrow-like linear tracks, and household/shelter crowding exposure; note that hygiene status alone does not exclude or confirm infestation.
• For pediculosis-capitis, localize subtype pattern (hair/scalp, clothing seams, pubic region), identify close-contact transmission risk, and assess secondary excoriation/infection burden.
• In pediculosis corporis concern, inspect clothing and bedding seams where lice may reside and eggs may be deposited.
• In pediculosis pubis concern, assess sexual-contact exposure and look for dark-brown speck contamination on skin or underwear.
• In inflammatory-pattern disease, expand trigger review to family history, medications, diet, hygiene products, and environmental exposures.
• In atopic-dermatitis patterns, assess family/personal atopy context, onset and duration, flexural distribution (for example antecubital and popliteal regions), excoriation burden, and lichenification.
• In atopic-dermatitis morphology review, document acute red oozing/crusted areas with possible blisters versus chronic dry thickened plaques.
• In atopic-dermatitis diagnostics, expect primarily clinical diagnosis; reserve targeted tests for unclear presentation or suspected allergy/immune contribution (for example biopsy, allergy testing, or selected immune labs) per provider plan.
• In eczema patterns, screen atopy history (asthma/allergic-rhinitis linkage), severe itch-scratch cycle, and triggers such as harsh soaps, frequent handwashing/bathing, sweat, rough fabrics, dry air, and food/environmental allergens.
• Include trigger review for fragrance/preservative exposure and potential food triggers (for example wheat, dairy, eggs) when flare correlation is plausible.
• Screen for secondary bacterial burden, including S. aureus colonization/infection cues, when excoriated skin worsens or fails to heal.
• In contact-dermatitis patterns, obtain direct exposure history (for example latex, plants, metals, detergents/cosmetics) and map lesion location to contact surface.
• In contact-dermatitis staging, document whether skin is predominantly acute vesicular, subacute crusted, or chronic lichenified because phase influences care priorities and follow-up.
• In contact-dermatitis patterns, document erythema, pruritus, burning, edema, papules/vesicles, and severe hemorrhagic-bullae cues when present.
• In severe pruritic dermatitis patterns, assess secondary bacterial-infection risk from scratching and skin-barrier disruption.
• In suspected allergic contact dermatitis, anticipate patch-testing workflow when trigger confirmation is clinically needed.
• In drug-reaction dermatitis assessment, reconcile recent topical/oral/parenteral medication exposures and document symptom-onset timing relative to doses.
• For patch-testing workflows, recognize that patch testing is mainly used for unresolved contact-dermatitis patterns and may be inappropriate in acute widespread dermatitis or selected drug-reaction contexts.
• In drug-reaction pathways, assess for systemic cues (for example fever, dyspnea, urticaria, or rapid progression) even when visible rash is limited or absent.
• In rosacea patterns, assess central-facial redness, flushing trend, visible small vessels, and papular lesion burden while distinguishing rosacea from acne by absent comedones.
• In darker skin tones, anticipate inflamed dermatitis areas that may appear darker, gray, or violaceous instead of bright erythema, and assess postinflammatory hyperpigmentation burden.
• In urticaria-pattern disease, assess airway and breathing immediately for angioedema or evolving respiratory compromise.
• In seborrheic-dermatitis patterns, assess scalp/face/auricular oil-gland regions for greasy yellow scale with pruritus/dandruff and note infant versus adult age-pattern distribution.
• In severe, sudden, or atypical seborrheic presentations, anticipate expanded differential workup (for example KOH scraping and selected immune/autoimmune testing) per provider plan.
• In eczema-pattern disease, assess for acute oozing/crusting versus chronic dry-thickened lichenified skin and secondary bacterial-infection cues from scratching.
• In acne/seborrheic-pattern disease, assess occlusive-product, hormonal, medication, and climate/sweating triggers.
• In acne patterns, classify lesion burden (blackheads/whiteheads, papules/pustules, nodules/cysts), document manipulation behavior (squeezing/popping), and trend scar risk plus psychosocial distress.
• In acne patterns, screen medication and trigger context (for example lithium, steroids, selected antiseizure agents, oil-based skin products, high stress burden, and cyclical menstrual flares).
• In generalized pruritus concern, evaluate for systemic contributors (for example renal, hepatic, endocrine, hematologic, medication-related, neurologic, or malignancy-linked conditions) and correlate with ordered lab trends.
• In psoriasis patterns, assess plaque distribution and trigger cluster (infection, cold weather, stress, smoking, obesity, HIV, medication exposure, burn/trauma history, and food sensitivities).
• In plaque-psoriasis patterns, inspect common sites (elbows, knees, scalp, lower back, and soles) for sharply demarcated thick erythematous plaques with silvery scale.
• In psoriasis pathways, screen for extracutaneous burden such as joint pain, nail thickening/change, and sleep disturbance that can indicate broader inflammatory impact.
• In psoriasis diagnostics, expect clinical diagnosis first; review ordered workup context (for example CBC, ESR, uric acid, and selected hepatic/renal or hepatitis testing) and biopsy use when morphology is unclear.
• In psoriasis severity review, use provider-documented scoring tools (for example PASI) when available to align nursing goals and expected treatment intensity.
• Grade inflammatory lesion burden and scar risk (for example nodulocystic acne or recurrent plaque inflammation) and assess psychosocial distress/body-image impact.

Nursing Interventions

• Implement condition-appropriate precautions and strict hand hygiene to reduce transmission.
• For draining or highly contagious lesions, apply standard plus transmission-based PPE strategy per setting policy and discard contaminated dressings safely.
• Protect skin barrier with gentle cleansing, moisture control, and trauma-minimizing care.
• Reinforce adherence to prescribed topical or systemic therapy and monitor response trends.
• For abscess-pattern disease, support warm-compress and cleansing routines and escalate when drainage procedure or deeper source control is required.
• For recurrent impetigo/abscess patterns, anticipate culture-guided carrier screening and decolonization plans (for example nasal-targeted protocols) per provider order.
• In cellulitis pathways, support edema reduction and portal-of-entry treatment while monitoring for systemic deterioration.
• In cellulitis with edema burden, support ordered compression strategy when clinically appropriate and no contraindication is present.
• Support transmission-reduction teaching: avoid direct lesion contact, avoid sharing oral-contact items during HSV outbreaks, and avoid sexual contact during active genital lesions.
• In varicella pathways, reinforce no-aspirin pediatric fever management, hydration support, and home isolation until lesions are crusted and dry.
• In pediatric viral-exanthem pathways, prioritize symptom support (fever/pain/pruritus control), hydration, and transmission-reduction teaching.
• Reinforce vaccine-prevention pathways when indicated (for example recombinant zoster and HPV vaccination).
• Reinforce antiviral-timing teaching for shingles because early treatment can reduce outbreak duration and severity.
• Reinforce moisture-control prevention for recurrent tinea: breathable footwear, regular sock changes, full drying of toe webs/folds, and shower-footwear use in communal wet areas.
• Reinforce that tinea capitis commonly requires oral antifungal therapy while topical products are adjunctive for spread reduction.
• In folliculitis pathways, reinforce gentle skin care, warm-compress support, and avoidance of scratching or shaving affected skin until healed.
• In folliculitis pathways, reinforce that many mild cases self-resolve; support ordered topical antibiotics (for example clindamycin or mupirocin) when lesions worsen or persist.
• In folliculitis pathways, escalate increasing redness, swelling, purulent drainage, or pain because provider-directed oral therapy (for example cephalexin-class coverage) may be required.
• For viral warts, reinforce that recurrence can occur after removal and that treatment choice may include topical chemicals (including lesion-only cantharidin vesicant application), cryotherapy, cautery/excision, or immune-based options per provider plan.
• For pediculosis-capitis pathways, teach environmental decontamination (hot wash/high-heat dry) plus timed retreatment and nit-combing to prevent reinfestation.
• For scabies/pediculosis-capitis outbreaks, reinforce close-contact evaluation/treatment and fomite control (laundering or sealed-bag isolation for nonwashable items; include brushes, clothing, bedding, and shared fabric surfaces).
• Include partner-management teaching when pubic-lice exposure is identified.
• In pediculosis pathways, reinforce subtype-directed treatment expectations (for example topical shampoos/creams for scalp or pubic lice, plus oral options in selected refractory or extensive disease).
• In eyelash pediculosis concern, escalate promptly because ophthalmic co-management may be required.
• In suspected staphylococcal-scalded-skin-syndrome severe cases, support contact precautions, fluid/temperature management, wound-dressing protection, and escalation to higher-acuity care when needed.
• For inflammatory flares, prioritize trigger minimization and barrier-support skin care (gentle soap substitutes, lukewarm water, post-bath moisturization, friction/irritant reduction).
• For contact dermatitis, eliminate suspected irritant/allergen exposure, apply ordered topical corticosteroids, and use antipruritic support (for example cetirizine-class antihistamine) as prescribed.
• In suspected dermatitis medicamentosa, stop suspected culprit medication per provider direction and escalate for urgent management when systemic symptoms or anaphylaxis cues emerge.
• For rosacea pathways, reinforce trigger reduction, monitor response to topical anti-infective regimens, and teach alcohol avoidance during metronidazole use plus sulfa-allergy reporting before sodium sulfacetamide therapy.
• For atopic-dermatitis flares, support ordered emollient/barrier therapy, antipruritic strategy (including oral antihistamine pathways when prescribed), hydration support, and secondary-infection prevention.
• For atopic-dermatitis skin care, prioritize fragrance-free oil-based ointments and routine moisturization because water-based lotions may provide shorter barrier support.
• For atopic-dermatitis escalation, monitor secondary-infection cues (increasing erythema, swelling, purulent or discolored drainage, and yellow crusting over excoriations) and notify the provider promptly.
• For moderate to severe inflammatory eczema patterns, support ordered escalation pathways such as topical/systemic corticosteroids, topical-calcineurin-inhibitors, biologic therapy, or phototherapy and monitor psychosocial burden.
• For persistent or worsening atopic-dermatitis pathways, support interdisciplinary referral planning (dermatology, allergy, wound/infectious-disease support when secondary infection is suspected, and nutrition support when healing concerns or food-trigger suspicion are present).
• In generalized exfoliative-dermatitis patterns, prioritize hemodynamic stabilization (IV fluids/electrolytes, temperature control) and hospital-based interdisciplinary escalation.
• In severe erythroderma patterns, monitor for systemic infection and perform ordered culture/diagnostic workflows promptly.
• For seborrheic-dermatitis pathways, reinforce scalp/skin routine with ordered antifungal or combined anti-inflammatory products (for example selenium sulfide, ketoconazole, zinc pyrithione, salicylic-acid combinations) and infant crust-softening removal technique.
• For generalized pruritus, focus on underlying-cause treatment while supporting skin protection (emollients/moisturizers, antipruritic regimens, and scratch-injury prevention).
• For acne pathways, reinforce gentle daily cleansing, water-based/noncomedogenic product selection, and avoidance of lesion manipulation; discuss diet-trigger patterns when clinically relevant.
• In selected acne cases, support provider-directed procedures such as comedone extraction by trained clinicians.
• For severe acne burden or significant psychosocial impact, support escalation/referral planning (for example dermatology) and reinforce that suppressive therapy often requires maintenance follow-up.
• For psoriasis pathways, combine trigger reduction with ordered topical therapies, moisturization, and phototherapy/systemic immunomodulation plans as indicated.
• For psoriasis topical-care plans, reinforce ordered agents such as corticosteroid creams/ointments, coal-tar preparations, or retinoid-based options, and monitor local tolerance.
• For moderate-severe psoriasis plans, coordinate phototherapy scheduling and monitor ordered systemic therapy for hepatic/renal trend changes and infection risk.
• In systemic immunomodulator pathways, monitor for serious infection cues (including tuberculosis or hepatitis risk context) and escalate promptly.
• For psoriasis education, reinforce trigger control (cold-dry climate exposure, alcohol excess, and stress burden), stress-reduction practice, and psychosocial support linkage.
• Escalate urticaria with facial/oropharyngeal swelling or breathing symptoms as emergency care.
• Escalate suspected systemic autoimmune involvement (for example lupus-pattern rash with multisystem symptoms) for broader diagnostic workup.
• Provide clear at-home lesion-care teaching and return precautions when wound/skin management continues after discharge.
• For adolescents and adults with visible dermatitis and social withdrawal or bullying-related distress, support coping assessment and referral pathways (for example counseling or behavioral-health support).
• Reinforce allergy-identification safety teaching for medication-triggered reactions (inform all care sites/providers and use medical-alert identification when severe reactions occurred).
• Escalate worsening infection signs, systemic compromise, or treatment nonresponse promptly.

Escalation Safety Point

Delayed recognition of spreading bacterial infection or severe inflammatory flare can lead to rapid deterioration.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
antibiotics	Topical and systemic regimens	Match route/intensity to severity and monitor for progression or failure.
antifungal-medications	Topical and oral antifungals	Reinforce full-course adherence and recurrence-prevention hygiene.
antihistamines	Class-based options	Support pruritus/urticaria symptom control; monitor sedation and escalation if airway risk appears.
topical-skin-protectants	Emollient and barrier products	Support epidermal barrier repair and reduce transepidermal water loss in eczema-pattern skin injury.
topical-corticosteroids	Cortisone-class topical options	Common first-line topical anti-inflammatory support in mild inflammatory dermatoses including psoriasis and eczema.
topical-calcineurin-inhibitors	Pimecrolimus pathways	Reinforce age limits and avoid continuous long-term use because malignancy-signal concerns exist.
antiparasitic-and-antihelminthic-medications	Topical metronidazole pathways	In rosacea care, avoid concurrent alcohol because disulfiram-like reactions can occur with systemic absorption.

Clinical Judgment Application

Clinical Scenario

A patient presents with painful erythematous skin plaques in one area and itchy scaling lesions in moist folds elsewhere.

• Recognize Cues: Mixed lesion patterns with different likely etiologies.
• Analyze Cues: One pattern suggests bacterial risk while another suggests fungal involvement.
• Prioritize Hypotheses: Immediate priority is preventing bacterial progression and identifying transmission risk.
• Generate Solutions: Start category-based assessment, implement precautions, and escalate red-flag findings.
• Take Action: Document morphology and distribution objectively, begin ordered therapies, and educate on hygiene and trigger control.
• Evaluate Outcomes: Erythema and symptom burden decline without systemic spread.

Related Concepts

• integumentary-system - Barrier disruption and age-related vulnerability shape condition risk.
• hygiene-factors-and-person-centered-planning - Daily hygiene barriers and routines influence recurrence.
• oral-perineal-and-catheter-hygiene-infection-prevention - Moisture and contamination control lower infection burden.
• wound-assessment-tools-and-documentation-standards - Objective lesion documentation supports safe trend tracking.
• healthcare-associated-infections - Infection prevention practices reduce spread in care settings.
• tinea-infection - Body-site-specific fungal skin disorder patterns and prevention priorities.
• varicella - Primary VZV infection with vesicular rash staging and high-risk complication screening.
• viral-skin-infections - Focused assessment and treatment priorities for shingles, HSV, and COVID-19 skin findings.
• hand-foot-and-mouth-disease - Pediatric enteroviral vesicular-exanthem pattern with hydration-focused care priorities.
• acne-vulgaris - Dedicated acne assessment and treatment pathway with lesion-severity and medication-safety focus.
• rosacea - Chronic inflammatory facial skin disorder with metronidazole and sulfacetamide treatment pathways.

Self-Check

1. Which lesion features best help distinguish infectious from inflammatory patterns?
2. What findings require immediate escalation for possible systemic involvement?
3. Which modifiable factors most reduce recurrence risk across common skin conditions?